logo
  

AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies - Quick Facts

AbbVie (ABBV) reported positive top-line results from the first of two studies of the phase 3 SELECT-AXIS 2 clinical trial evaluating RINVOQ in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy. RINVOQ met its primary endpoint of ASAS 40 response and all ranked secondary endpoints at week 14. Safety data were consistent with SELECT-AXIS 1, previous phase 3 studies in other indications, and the known safety profile of RINVOQ, with no new risks identified.

Separately, AbbVie reported positive top-line results from study 2 of the phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis, showing RINVOQ met the primary endpoint of Assessment in ASAS 40 response and the majority of ranked secondary endpoints at week 14. Safety data were consistent with SELECT-AXIS 1, previous phase 3 studies in other indications, and the known safety profile of upadacitinib, with no new risks identified.

RINVOQ 15 mg is approved by the FDA for adults with moderately to severely active rheumatoid arthritis. Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT